| Full description or abstract |
In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years. Although gene expression signatures have been associated with outcome, there is no method to predict recurrence based on combined clinical, pathology, and genomic data (from tumor and cirrhotic tissue). We evaluated gene expression signatures associated with outcome in a large cohort of patients with early stage (Barcelona-Clinic Liver Cancer 0/A), single-nodule HCC and heterogeneity of signatures within tumor tissues. |
| Source publication |
Pubmed 21320499 Authors: Villanueva A,Hoshida Y,Battiston C,Tovar V,Sia D,Alsinet C,Cornella H,Liberzon A,Kobayashi M,Kumada H,Thung SN,Bruix J,Newell P,April C,Fan JB,Roayaie S,Mazzaferro V,Schwartz ME,Llovet JM |
